Clinicians Report Success with First Test of Drug in a Patient with Life-
First patient in the U.S. with immune thrombotic thrombocytopenic purpura to receive the drug is in remission.
First patient in the U.S. with immune thrombotic thrombocytopenic purpura to receive the drug is in remission.
Investigating the impact of long-term proton pump inhibitor use.
Read the statements from the family of Rick Slayman, as well as his care team at Massachusetts General Hospital.
The results of this analysis can inform the development of a clinical decision support system to aid clinicians in the evaluation of hospitalized individuals with suspected TB.
This study was designed to investigate which cellular, transcriptional and signaling programs are associated with the development of colitis in cancer patients being treated with immune checkpoint inhibitors (ICIs).
At the Sean M. Healey & AMG Center for ALS, compassionate clinical care converges with cutting-edge research every day. The laboratories at the Charlestown Navy Yard are humming with investigators researching the latest breakthroughs in ALS and bringing us closer to a cure.
Marc Succi, MD, a physician investigator in the Department of Radiology at Massachusetts General Hospital, associate chair of innovation and commercialization at Mass General Brigham Enterprise Radiology and an assistant professor of Radiology at Harvard Medical School, is the lead author of a recently published paper in Journal of Arthplasty, Orthopaedic Surgery Volume Trends During the COVID-19 Pandemic and Post-Vaccination Era: Implications for Healthcare Planning
Rebecca Gillani, MD, PhD, a physician investigator in the Department of Neurology at Massachusetts General Hospital and an Instructor in Neurology at Harvard Medical School, is the lead author of a recently published paper in Brain, Behavior, and Immunity; Instability of Excitatory Synapses in Experimental Autoimmune Encephalomyelitis and the Outcome for Excitatory Circuit Inputs To Individual Cortical Neurons.
Zirui Song, MD, PhD, a physician investigator in the Department of Medicine at Massachusetts General Hospital and an associate professor of Health Care Policy and Medicine at Harvard Medical School, is the senior author of a recently published perspective in the New England Journal of Medicine, Corporate Medicine 2.0 — Special Purpose Acquisition Companies in the United States. The article’s lead author is Nishant Uppal, MD, MBA, a resident at Brigham and Women’s Hospital.
In a randomized clinical trial including adults who vaped nicotine e-cigarettes but did not smoke cigarettes, a 12-week course of cytisinicline, a plant-based medication, was more effective at helping people quit e-cigarettes than placebo when both were combined with behavioral support.
Members of the media can reach the News and Public Affairs staff by phone.